Drug Profile
DRL 16536
Alternative Names: DRF 16536Latest Information Update: 26 May 2009
Price :
$50
*
At a glance
- Originator Dr Reddys Laboratories
- Developer Dr Reddys Laboratories; Perlecan Pharma
- Class Antihyperglycaemics
- Mechanism of Action Protein kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 26 May 2009 Discontinued - Phase-I for Diabetes mellitus in India (unspecified route)
- 03 Oct 2005 Preclinical trials in Lipid metabolism disorders in India (unspecified route)